Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore. more
Time Frame | WVE | Sector | S&P500 |
---|---|---|---|
1-Week Return | -16.94% | -2.06% | -0.55% |
1-Month Return | -0.39% | -1.92% | 2.72% |
3-Month Return | 134% | -10.4% | 7.66% |
6-Month Return | 124.17% | -4.6% | 10.15% |
1-Year Return | 185.08% | 4.06% | 27.53% |
3-Year Return | 268.88% | 1.94% | 32.31% |
5-Year Return | -16.83% | 36.48% | 89.2% |
10-Year Return | -20% | 97.46% | 194.59% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 15.98M | 20.08M | 40.96M | 3.65M | 113.31M | [{"date":"2019-12-31","value":14.11,"profit":true},{"date":"2020-12-31","value":17.72,"profit":true},{"date":"2021-12-31","value":36.15,"profit":true},{"date":"2022-12-31","value":3.22,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Cost of Revenue | 175.43M | 124.17M | 121.88M | 10.11M | 9.21M | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":70.78,"profit":true},{"date":"2021-12-31","value":69.47,"profit":true},{"date":"2022-12-31","value":5.77,"profit":true},{"date":"2023-12-31","value":5.25,"profit":true}] |
Gross Profit | (159.45M) | (104.09M) | (80.91M) | 3.65M | 104.10M | [{"date":"2019-12-31","value":-153.17,"profit":false},{"date":"2020-12-31","value":-99.99,"profit":false},{"date":"2021-12-31","value":-77.73,"profit":false},{"date":"2022-12-31","value":3.51,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Margin | (997.61%) | (518.44%) | (197.52%) | 100.00% | 91.88% | [{"date":"2019-12-31","value":-997.61,"profit":false},{"date":"2020-12-31","value":-518.44,"profit":false},{"date":"2021-12-31","value":-197.52,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":91.88,"profit":true}] |
Operating Expenses | 224.30M | 173.45M | 167.98M | 166.37M | 181.30M | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":77.33,"profit":true},{"date":"2021-12-31","value":74.89,"profit":true},{"date":"2022-12-31","value":74.17,"profit":true},{"date":"2023-12-31","value":80.83,"profit":true}] |
Operating Income | (208.32M) | (153.38M) | (127.02M) | (162.72M) | (68.00M) | [{"date":"2019-12-31","value":-20831700000,"profit":false},{"date":"2020-12-31","value":-15337700000,"profit":false},{"date":"2021-12-31","value":-12701600000,"profit":false},{"date":"2022-12-31","value":-16272000000,"profit":false},{"date":"2023-12-31","value":-6799600000,"profit":false}] |
Total Non-Operating Income/Expense | 14.71M | 2.61M | - | 3.15M | - | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":17.75,"profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":21.41,"profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Pre-Tax Income | (193.64M) | (150.75M) | (122.45M) | (161.14M) | (58.19M) | [{"date":"2019-12-31","value":-19363800000,"profit":false},{"date":"2020-12-31","value":-15075100000,"profit":false},{"date":"2021-12-31","value":-12244900000,"profit":false},{"date":"2022-12-31","value":-16114200000,"profit":false},{"date":"2023-12-31","value":-5819000000,"profit":false}] |
Income Taxes | (14.14M) | (841.00K) | (204.00K) | 681.00K | (677.00K) | [{"date":"2019-12-31","value":-2076.65,"profit":false},{"date":"2020-12-31","value":-123.49,"profit":false},{"date":"2021-12-31","value":-29.96,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-99.41,"profit":false}] |
Income After Taxes | (179.50M) | (149.91M) | - | (161.82M) | - | [{"date":"2019-12-31","value":-17949600000,"profit":false},{"date":"2020-12-31","value":-14991000000,"profit":false},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":-16182300000,"profit":false},{"date":"2023-12-31","value":"-","profit":true}] |
Income From Continuous Operations | (193.64M) | (149.91M) | (122.25M) | (161.82M) | (57.51M) | [{"date":"2019-12-31","value":-19363800000,"profit":false},{"date":"2020-12-31","value":-14991000000,"profit":false},{"date":"2021-12-31","value":-12224500000,"profit":false},{"date":"2022-12-31","value":-16182300000,"profit":false},{"date":"2023-12-31","value":-5751300000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (179.50M) | (149.91M) | (122.25M) | (161.82M) | (57.51M) | [{"date":"2019-12-31","value":-17949600000,"profit":false},{"date":"2020-12-31","value":-14991000000,"profit":false},{"date":"2021-12-31","value":-12224500000,"profit":false},{"date":"2022-12-31","value":-16182300000,"profit":false},{"date":"2023-12-31","value":-5751300000,"profit":false}] |
EPS (Diluted) | (5.71) | (3.98) | (2.37) | (2.13) | (0.55) | [{"date":"2019-12-31","value":-571,"profit":false},{"date":"2020-12-31","value":-398,"profit":false},{"date":"2021-12-31","value":-237,"profit":false},{"date":"2022-12-31","value":-213,"profit":false},{"date":"2023-12-31","value":-55,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
WVE | |
---|---|
Cash Ratio | 1.82 |
Current Ratio | 1.90 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
WVE | |
---|---|
ROA (LTM) | -34.04% |
ROE (LTM) | -243.82% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
WVE | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.60 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.40 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
WVE | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 38.27 |
P/B | 14.48 |
Price/FCF | NM |
EV/R | 32.97 |
EV/Ebitda | NM |
PEG | NM |
Wave Life Sciences Ltd (WVE) share price today is $13.09
Yes, Indians can buy shares of Wave Life Sciences Ltd (WVE) on Vested. To buy Wave Life Sciences Ltd from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in WVE stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Wave Life Sciences Ltd (WVE) via the Vested app. You can start investing in Wave Life Sciences Ltd (WVE) with a minimum investment of $1.
You can invest in shares of Wave Life Sciences Ltd (WVE) via Vested in three simple steps:
The 52-week high price of Wave Life Sciences Ltd (WVE) is $16.74. The 52-week low price of Wave Life Sciences Ltd (WVE) is $3.5.
The price-to-earnings (P/E) ratio of Wave Life Sciences Ltd (WVE) is
The price-to-book (P/B) ratio of Wave Life Sciences Ltd (WVE) is 14.48
The dividend yield of Wave Life Sciences Ltd (WVE) is 0.00%
The market capitalization of Wave Life Sciences Ltd (WVE) is $2.05B
The stock symbol (or ticker) of Wave Life Sciences Ltd is WVE